Zobrazeno 1 - 8
of 8
pro vyhledávání: ''
Autor:
Geeta S. Bhagwat, Rajani B. Athawale, Rajeev P. Gude, Shadab Md, Nabil A. Alhakamy, Usama A. Fahmy, Prashant Kesharwani
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2023)
Externí odkaz:
https://doaj.org/article/dffc91008a7a4b85aa19bf9543a2a1b0
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Introduction: Tamoxifen (TAM) is the most commonly used hormone therapeutic drug for the treatment of estrogen receptor-positive (ER+) breast cancer. 30%–70% of clinical breast cancer patients use natural products, which may increase the likelihood
Externí odkaz:
https://doaj.org/article/090ad13dff61496592c735b5ec4df1a9
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
Tamoxifen is a drug commonly used in the treatment of breast cancer, especially for postmenopausal patients. However, its efficacy is limited by the development of drug resistance. Downregulation of estrogen receptor alpha (ERα) is an important mech
Externí odkaz:
https://doaj.org/article/3f3845b7f699461d99a5b10bd90c9c44
Autor:
Geeta S. Bhagwat, Rajani B. Athawale, Rajeev P. Gude, Shadab Md, Nabil A. Alhakamy, Usama A. Fahmy, Prashant Kesharwani
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
Breast cancer is conventionally treated by surgery, chemotherapy and radiation therapy followed by post operational hormonal therapy. Tamoxifen citrate is a best option to treat breast cancer because its selective estrogen receptor modulation activit
Externí odkaz:
https://doaj.org/article/9424c8921d7b41599d2719152760098e
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Background: Earlier studies have indicated a relatively higher risk of occurring meningioma among female breast cancer survivors and have suggested that tamoxifen might decrease this risk. The present study evaluated whether tamoxifen use in breast c
Externí odkaz:
https://doaj.org/article/bf979efddba84bcdb55031a176e88797
Publikováno v:
Frontiers in Pharmacology, Vol 8 (2017)
Background and Objectives: There are inconsistent results about the association between ischemic cerebrovascular disease and tamoxifen use in women with breast cancer. The study aimed to evaluate the association between the risk of ischemic cerebrova
Externí odkaz:
https://doaj.org/article/41b68289e0d94d849ce8075efa5f79a2
Publikováno v:
Frontiers in Pharmacology, Vol 8 (2017)
Background and Objectives: Little is known about the association between tamoxifen use and Alzheimer’s disease in women with breast cancer. The study aimed to explore the association between tamoxifen use and Alzheimer’s disease in aged women wit
Externí odkaz:
https://doaj.org/article/d8005b92ca994301b50a238ba1045986
Autor:
Werner Schroth, Stefan Winter, Thomas Mürdter, Elke Schaeffeler, Diana Eccles, Bryony Eccles, Balram Chowbay, Chiea C. Khor, Arafat Tfayli, Nathalie K. Zgheib, Michel Eichelbaum, Matthias Schwab, Hiltrud Brauch
Publikováno v:
Frontiers in Pharmacology, Vol 8 (2017)
Purpose: Prediction of impaired tamoxifen (TAM) to endoxifen metabolism may be relevant to improve breast cancer treatment, e.g., via TAM dose increase. The polymorphic cytochrome P450 2D6 (CYP2D6) strongly determines an individual’s capacity for e
Externí odkaz:
https://doaj.org/article/88e85bdd41744421ab1879bce1e36e3e